The EVA partnership is driven by an experienced team with deep expertise in both medical research and artificial intelligence. Tove Holm-Larsen, Guest Professor of Health Economic at the University of Ghent and head of Silvi.ai, has over 20 years of experience in clinical drug research and is dedicated to leveraging AI’s potential in developing new treatments. Rasmus Hvingelby, Chief Technology Officer (CTO) at Silvi.ai, is an expert in machine learning and ensures that EVA is built on the industry’s best AI engine.
To ensure that EVA remains at the forefront of the latest research and technology, the partnership has gathered a range of leading experts and researchers in their respective fields.
Among our project partners are Anders Søgaard, Professor of AI at the University of Copenhagen, and Linda Aagaard Thomsen, Head of Department at the Danish Medicines Council, both contributing expertise in artificial intelligence and medical evaluations. Similarly, Claus Rehfeld from Nordic Healthcare Group specializes in translating data into practical clinical applications and Karel Everaert, Professor of Functional Urology at Ghent University, provides specialized knowledge in urology and pharmaceutical innovation.
Within biostatistics and clinical epidemiology, the partnership is represented by Christian Dahlendorff, Chief Biostatistics Consultant at the Danish Medicines Council as well as Anton Pottegård and Jesper Hallas, both Professors of Clinical Epidemiology at Odense University Hospital. Furthermore, Inge Tarnow, Clinical Development Manager at Klox, and Mikkel Walmar, Project Manager at the same organization, play a key role in developing EVA.
Finally, we have high quality input from the Pharmaceutical industry through the collaboration with Thomas Delvin, Vice President and Head of Global Clinical Development at LEO Pharma, as well as Madina Saidj, Manager of Health Economics, Market Access and Reimbursement and Agnete Dissing, Real World Partner Lead from Johnson & Johnson.
This broad expertise forms the foundation for EVA’s development, ensuring that our solutions are practically applicable and create real value for patients.